AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00988325
Drug: Tamiflu
RxNorm normalized name: Tamiflu
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral repeating dose
Trial: NCT00728078
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: thalidomide 50mg tid for 6 months
Trial: NCT01785095
Drug: FSH (Follicle Stimulating Hormone)
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00301821
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00301821
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02931591
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is administered as an oral solution
Trial: NCT02931591
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone- no specific band
Trial: NCT03961971
Drug: MBG453
RxNorm normalized name: Anti-tim-3 monoclonal antibody mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Trial: NCT02060383
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin.
Trial: NCT00238628
Drug: Bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00238628
Drug: Iressa
RxNorm normalized name: Iressa
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00257829
Drug: Methazolamide
RxNorm normalized name: Methazolamide
DrugBank: Methazolamide (DB00703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00257829
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00314678
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00314678
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00314678
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00121836
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg IV on Day 1 of each 3-week cycle
Trial: NCT01339026
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
Trial: NCT01339026
Drug: Plavix
RxNorm normalized name: Plavix
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
Trial: NCT03491683
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (TMZ) will be given daily during radiation therapy (RT) at a dose of 75 milligrams per square meter (mg/m\^2).
Trial: NCT01225536
Drug: ARQ 736
RxNorm normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
Trial: NCT02172170
Drug: BI 10773 single rising dose
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03998176
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
RxNorm normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: B/F/TAF single tablet formulation
Trial: NCT00024050
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00024050
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00880685
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-30mg, daily for 8 weeks
Trial: NCT02438722
Drug: Afatinib Dimaleate
RxNorm normalized name: afatinib dimaleate
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00830245
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150mg/day
Trial: NCT00541463
Drug: MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00541463
Drug: Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02398773
Drug: F-18 16 Alpha-Fluoroestradiol
RxNorm normalized name: F-18 16 alpha-Fluoroestradiol
DrugBank: Fluoroestradiol F-18 (DB15690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00280501
Drug: Sulpiride (drug)
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (Dogmatil 200mg-tablet, Synthélabo Groupe, Le Plessis Robinson, France) Dose: one half of 200 mg tablet oral single dose
Trial: NCT02547714
Drug: Secukinumab (AIN457)
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
Trial: NCT02793011
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral dexamethasone elixir (0.5mg/ml or 4 mg/ml) mixed with Ora-sweet or simple syrup to mask the taste. Or 1 mg or 4 mg dexamethasone capsules if age appropriate
Trial: NCT00132561
Drug: Sulfadoxine/pyrimethamine and artesunate
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005863
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005863
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005863
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005863
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00075673
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Trial: NCT00978432
Drug: Doublet (RAD001 and LBH589)
RxNorm normalized name: sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
Trial: NCT00631800
Drug: Pagibaximab (formerly BSYX-A110)
RxNorm normalized name: Pagibaximab
DrugBank: Pagibaximab (DB17786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
Trial: NCT01168700
Drug: aged garlic extract
RxNorm normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
DrugBank: Garlic (DB10532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged garlic extract, 1.2 g per day for 12 weeks
Trial: NCT02752971
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03028350
Drug: Ifetroban Oral Capsule
RxNorm normalized name: Ifetroban
DrugBank: Ifetroban (DB12321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with oral ifetroban daily for 8 weeks
Trial: NCT00084617
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00084617
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04585152
Drug: Rituximab Biosimilar
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
Trial: NCT03703570
Drug: KW-6356
RxNorm normalized name: KW-7158
DrugBank: KW-6356 (DB17080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT03422627
Drug: Efavaleukin Alfa
RxNorm normalized name: Efavaleukin alfa
DrugBank: Efavaleukin alfa (DB16149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: This study will be conducted as a multiple ascending dose (MAD) study. Each dosing cohort will consist of between 3 and 6 subjects who will receive efavaleukin alfa subcutaneously (SC) either every week or every 2 weeks plus protocol permitted background therapy for 52 weeks. At the discretion of the Sponsor, following discussion and agreement between the principal investigator and medical monitor, subjects responding to efavaleukin alfa (as assessed by the end of week 50), who wish to continue treatment, may continue to receive efavaleukin alfa treatment at their current dosing regimen for up to an additional 208 weeks through an extended dosing period. All subjects who continue to receive efavaleukin alfa during the extended dosing period will be reevaluated every 6 months for their response to treatment.~Phase 2: All subjects will receive the recommended phase 2 dose (RP2D) of efavaleukin alfa for 52 weeks.
Trial: NCT03776487
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03920618
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
Trial: NCT03920618
Drug: Tenofovir Disoproxil Fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
Trial: NCT03920618
Drug: Tenofovir Alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
Trial: NCT02228031
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session
Trial: NCT04329650
Drug: Siltuximab
RxNorm normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.
Trial: NCT04329650
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A dose of 6mg/24 hours of dexamethasone during 10 days will be administered orally or by intravenous infusion.
Trial: NCT01560091
Drug: silodosin
RxNorm normalized name: Silodosin
DrugBank: Silodosin (DB06207)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 8mg PO Qday
Trial: NCT01560091
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4mg PO Qday
Trial: NCT00930722
Drug: quinapril
RxNorm normalized name: Quinapril
DrugBank: Quinapril (DB00881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: per label as non interventional study
Trial: NCT00745199
Drug: cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks
Trial: NCT00151970
Drug: Methylphenidate Transdermal System
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MTS 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes
Trial: NCT00151970
Drug: Concerta
RxNorm normalized name: Concerta
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
Trial: NCT00250653
Drug: Saredutant succinate (SR48968C)
RxNorm normalized name: succinate
DrugBank: Saredutant (DB06660)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003370
Drug: irofulven
RxNorm normalized name: Irofulven
DrugBank: Irofulven (DB05786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00295633
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
Trial: NCT00295633
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
Trial: NCT00295633
Drug: pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
Trial: NCT01087866
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01087866
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00295633
Drug: rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
Trial: NCT00295633
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, 500-2500 mg, as needed (12 months LT)
Trial: NCT03308942
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib is an orally available, potent, highly selective poly adenosine diphosphate- ribose (poly ADP-ribose) polymerase-1 (PARP-1) and PARP-2 inhibitor. It will be available as 100 milligrams (mg) capsules and will be administered as 2 X 100 mg capsules (200 mg per day) orally once daily (QD).
Trial: NCT00131430
Drug: taranabant
RxNorm normalized name: Taranabant
DrugBank: Taranabant (DB06624)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02582762
Drug: Nail gel
RxNorm normalized name: Urea Nail Gel
DrugBank: Garden snail mucin (DB14244)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply nail gel on affected nails twice daily for 2 months
Trial: NCT04562025
Drug: UC-MSCs
RxNorm normalized name: UC-MSCs
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times of UC-MSCs (1\*10E6 UC-MSCs/kg body weight/100mL saline containing 1% human albumin intravenously at week 1,week 2, week 3).
Trial: NCT02761057
Drug: Cabozantinib S-malate
RxNorm normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02761057
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02761057
Drug: Savolitinib
RxNorm normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02761057
Drug: Sunitinib Malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02221622
Drug: Allopregnanolone injection (intravenous solution)
RxNorm normalized name: Allopregnanolone
DrugBank: Brexanolone (DB11859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopregnanolone intravenous infusion
Trial: NCT02232139
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The participants receive the pharmacological premedication before the surgery anyway
Trial: NCT01940094
Drug: 5 mg Prednisone
RxNorm normalized name: prednisone 5 MG
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will remain on daily prednisone dose of 5 mg
Trial: NCT01940094
Drug: 0 mg Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
Trial: NCT00216840
Drug: Calcipotriol plus betamethasone dipropionate (LEO80185 gel)
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00686335
Drug: Cortancyl
RxNorm normalized name: Cortancyl
DrugBank: Prednisone acetate (DB14646)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).
Trial: NCT03191578
Drug: RUTI®
RxNorm normalized name: RUTI® Vaccine
DrugBank: RUTI® Vaccine (DB15853)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of RUTI®
Trial: NCT00589784
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
Trial: NCT02145507
Drug: AS-3 (Control)
RxNorm normalized name: cefazolin
DrugBank: Adenine (DB00173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit
Trial: NCT05867342
Drug: Epinephrin
RxNorm normalized name: Epinephrin
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application of 2 pieces of Epinephrin (1:1,000)-soaked cottonoid in nasal cavity
Trial: NCT05867342
Drug: 1% lidocaine with epinephrin 1:100,000
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 ml intranasal infiltration of 1% lidocaine with epinephrine (1:100,000) at 2 sites (2 ml infiltration at each site)
Trial: NCT05867342
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 ml intranasal infiltration of saline at 2 sites (2 ml infiltration at each site)
Trial: NCT00723203
Drug: panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
Trial: NCT00653042
Drug: Nesiritide
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00470184
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT01131351
Drug: Delamanid
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OPC-67683 film-coated tablets
Trial: NCT01798992
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01798992
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no